Serum antimüllerian hormone is not predictive of oocyte quality in vitro fertilization.
Level 3 - non-randomized controlled study
Retrospective observational cohort study
PubMed 19446790 · doi:10.1016/j.ando.2009.03.007
What was done
A retrospective cohort study was conducted in 559 women undergoing in vitro fertilization (IVF) between January 2007 and December 2007 at Bretonneau University Hospital of Tours. Serum antimüllerian hormone (AMH) was measured using an ultrasensitive ELISA. The total number of oocytes, mature oocyte rate, fertilization rate, early embryo quality, and clinical pregnancy rate were evaluated relative to AMH levels.
What was found
Serum AMH was significantly lower in patients with few oocytes collected. AMH was not predictive of oocyte nuclear maturity, fertilization rate, or early embryo quality. Low AMH levels did not preclude clinical pregnancy, and no cutoff value could be established to predict clinical pregnancy. The abstract reports no numeric values, effect sizes, or p-values.
Why it matters
The findings indicate that AMH functions primarily as a biomarker of quantitative ovarian reserve rather than oocyte or embryo quality in IVF cycles.
Limits
This was a retrospective, single-center study. The abstract omits all numerical data, confidence intervals, and statistical test values, and it does not report adjustment for critical confounders such as female age, stimulation protocols, or male factor infertility.
Cited by
- supports Anti-Müllerian hormone (AMH) testing provides a measure of egg quantity (ovarian reserve) but does not assess egg quality.